| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRKRIR |
| Uniprot No | O43422 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 612-761aa |
| 氨基酸序列 | MGQLKFNTSEEHHADMYRSDLPNPDTLSAELHCWRIKWKHRGKDIELPSTIYEALHLPDIKFFPNVYALLKVLCILPVMKVENERYENGRKRLKAYLRNTLTDQRSSNLALLNINFDIKHDLDLMVDTYIKLYTSKSELPTDNSETVENT |
| 预测分子量 | 33.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRKRIR重组蛋白的3篇虚构参考文献示例(基于研究领域常见方向推测内容)：
1. **文献名称**：*"Recombinant PRKRIR Protein Suppresses Viral Replication by Modulating RIG-I Signaling Pathway"*
**作者**：Chen L., et al.
**摘要**：研究利用大肠杆菌表达系统成功获得高纯度PRKRIR重组蛋白，并证明其通过抑制RIG-I信号通路负调控I型干扰素产生，从而限制RNA病毒的复制能力。
2. **文献名称**：*"Structural Characterization of PRKRIR and Its Interaction with MAVS in Antiviral Immunity"*
**作者**：Zhang Y., et al.
**摘要**：通过X射线晶体学解析PRKRIR重组蛋白结构，揭示其与MAVS蛋白的相互作用界面，阐明其通过阻断MAVS聚集抑制过度免疫反应的分子机制。
3. **文献名称**：*"PRKRIR Recombinant Protein Attenuates Autoimmune Inflammation in Murine Models"*
**作者**：Kim H., et al.
**摘要**：在类风湿性关节炎小鼠模型中，外源性PRKRIR重组蛋白通过负反馈调节JAK-STAT通路显著减轻炎症反应，提示其潜在治疗自身免疫疾病的应用价值。
(注：以上文献为基于领域知识的模拟内容，实际文献需通过PubMed等学术数据库检索)
**Background of PRKRIR Recombinant Protein**
PRKRIR (Protein Kinase, Interferon-Inducible Double Stranded RNA-Dependent Inhibitor, also known as RAX or P58IPK) is a regulatory protein involved in modulating innate immune responses, particularly within interferon (IFN) signaling pathways. It functions as an endogenous inhibitor of EIF2AK2 (PKR), a serine/threonine kinase activated during viral infection or cellular stress. PKR plays a critical role in antiviral defense by phosphorylating the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α), halting global protein synthesis to limit viral replication. However, uncontrolled PKR activation can lead to excessive inflammation or apoptosis. PRKRIR binds directly to PKR, suppressing its kinase activity and preventing aberrant immune activation, thereby maintaining cellular homeostasis.
Recombinant PRKRIR protein is engineered in vitro using expression systems like *E. coli* or mammalian cells, often fused with tags (e.g., His or GST) for purification and detection. Its production enables detailed studies of PKR regulation, host-pathogen interactions, and stress response mechanisms. Researchers utilize PRKRIR recombinant protein to investigate molecular mechanisms in viral evasion strategies, autoimmune disorders (e.g., lupus, neurodegenerative diseases), and cancers where PKR signaling is dysregulated. It also serves as a tool for screening therapeutic agents targeting PKR-mediated pathways.
The development of PRKRIR recombinant protein underscores its importance in dissecting immune regulation and developing interventions for diseases linked to disrupted protein kinase activity. Its application spans basic research, drug discovery, and biotechnology, highlighting its relevance in both academic and clinical settings.
×
